Glimmers of Hope for Targeting p53.

In two ongoing phase I trials, PC14586, a Y220C-selective structural corrector of mutant p53, and BI 907828, an MDM2-p53 antagonist, appear safe and tolerable, showing signs of efficacy. These emerging data offer hope that a key tumor suppressor may not be as undruggable as previously thought.